Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 349

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 349
---
               |           - |   |
| Class A common stock; $0.0001 par value; 1,000,000,000 shares authorized; 2,415,883 shares issued and outstanding at December 31, 2024 |     |              |         242 |   |     |               |           - |   |
| Common stock, $0.0001 par value, 45,350,000 shares authorized, 5,845 shares issued and outstanding at December 31, 2023                |     |              |           - |   |     |               |           1 |   |
| Additional paid-in capital                                                                                                             |     |              |  67,142,046 |   |     |               |   1,032,125 |   |
| Stock subscription receivable                                                                                                          |     |              |  (1,295,444 | ) |     |               |           - |   |
| Accumulated deficit                                                                                                                    |     |              | (70,917,853 | ) |     |               | (43,089,821 | ) |
| Total stockholders’ deficit                                                                                                            |     |              |  (1,894,563 | ) |     |               | (42,057,695 | ) |
| Total liabilities, convertible preferred stock and stockholders’ deficit                                                               |     | $            |   6,206,929 |   |     | $             |   5,126,302 |   |

See accompanying notes to the consolidated financial statements Reflects a 1-for-100 reverse stock split effective January 8, 2025 F-32 CERO THERAPEUTICS HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS

|                                                            |     |            |      For the 
  period from 
 February 14, 
 2024 through 
 December 31, 
         2024 |   |     |              |      For the 
  period from 
   January 1, 
 2024 through 
 February 13, 
         2024 |   |     |              |      For the 
   year ended 
 December 31, 
         2023 |   |
|:-----------------------------------------------------------|:----|:-----------|-------------:|:--|:----|:-------------|-------------:|:--|:----|:-------------|-------------:|:--|
|                                                            |     | -Successor |              |   |     | -